AcuityMD launches AcuityAI Artifacts to turn chat insights into structured, shareable outputs. MedTech commercial teams can now reuse and build on AI-generated intelligence across recurring workflows, reducing repetitive work for AcuityAI users BOSTON - October 28, 2026 - AcuityMD, the AI platform for MedTech, today announced AcuityAI Artifacts, a new capability that transforms AI-generated insights into structured, reusable content for commercial teams. With Artifacts, users can turn AcuityAI conversations into call plans, market analyses, account comparisons, targeting lists, and reports that can be easily saved, refined, and exported. Artifacts ensure valuable insights extend beyond a single conversation, enabling teams to continuously build on and benefit from that intelligence. Artifacts can be generated from any information available in AcuityAI. The agent automatically selects the most appropriate output format based on the user's request such as a chart, ranked list, or comparison table. Users can take these documents based on AcuityAI responses and refine them over time as well as export them as polished AcuityMD-branded content. "AcuityAI already gives commercial teams the answers they need, and now Artifacts makes those answers something the whole team can use," said Brian Collins, Chief Product Officer at AcuityMD. "A rep can build a targeting list once and share it with their manager; a commercial leader can carry the same account view from one QBR to the next instead of rebuilding it every time. This is how AI evolves from just answering individual questions to becoming an integral part of how a commercial team collaborates and makes decisions." AcuityAI Artifacts is available now to all AcuityMD customers. About AcuityMD. AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies - including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD ranked No. 316 on the 2026 Inc. 5000 list of the fastest-growing private companies in America and was named to Forbes' 2025 "Next Billion-Dollar Startups" list - an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation. Media contact: Lisa Barbadora, Barbadora INK for AcuityMD +1 (610) 420-3413

AcuityMD, an AI platform for medical technology (MedTech), has launched a research agent in its AcuityAI product that cuts market analysis from weeks to minutes. The Boston company announced the tool on October 13, 2026. The agent delivers company, brand, and product-level market share, pricing comparisons, and patient pathway analyses, and uses them to calculate total addressable market size. It draws on AcuityMD's proprietary MedTech data model linking physicians, facilities, procedures, and reimbursement. Each step is cited, and analyses can be re-run as new data arrives. The agent can be enabled for select users. AcuityMD is demonstrating it at its Flywheel 2026 conference in Philadelphia and at The MedTech Conference in Boston, October 18-21. The company says over 500 MedTech firms use its platform, including 16 of the top 20.

AcuityMD launches research agent in AcuityAI to take MedTech market analysis from weeks to minutes. Grounded in MedTech data, the agent delivers cited, re-runnable analyses for strategy and M&A October 13, 2026 BOSTON - October 13, 2026 - AcuityMD, the AI platform for MedTech, today introduced advanced market analysis in AcuityAI, powered by a new research agent that delivers company, brand, and product-level market share, pricing comparisons, and patient pathway analyses to calculate total addressable market size in minutes. MedTech leaders gain fast, accurate market analysis - a traditionally time-consuming process - to improve long-term decision-making. MedTech market analysis typically requires piecing together information across claims data, syndicated reports, clinical research, internal data, and more, which customers say takes weeks or even months. And while general-purpose AI has made research faster, it lacks the right data and industry context required for high-stakes decisions. AcuityMD's research agent closes that gap. It is grounded in the company's proprietary MedTech ontology that connects physicians, facilities, networks, procedures, and reimbursement. The agent runs multi-step analyses scoped to a company's market, cited at every step, and re-runnable as new data arrives, giving leaders a defensible starting point for planning, investment, and mergers and acquisitions. "AcuityAI brings objective data into our diligence process, proving particularly valuable in our understanding of markets and how they're evolving over time," said Chris Murray, Principal at MVM Partners, an investment company with a global outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. AcuityMD's new agent, which can be enabled for select users, allows MedTech leaders to answer questions such as the following: * Competitive strategy: Where are AcuityMD, Inc. gaining or losing share against competitors, and how does its pricing compare? * Upstream marketing and product management: How large is the market for a new indication, how do patients move through care today, and which segments warrant closer investigation? * M&A and corporate strategy: What does the market data indicate about a potential acquisition target? "MedTech teams now have a faster path from a market question to a decision, directly within AcuityAI," said Brian Collins, AcuityMD Chief Product Officer. "Our research agent brings together deep MedTech context and real-world industry data and activity, not directional estimates from syndicated reports, general-purpose datasets, or vague, forward-looking opinion surveys. Research that used to take weeks or even months can now be completed in minutes." AcuityMD is demonstrating the research agent at its annual Flywheel 2026 conference (October 13-14) in Philadelphia and at booth #1102 at The MedTech Conference (October 18-21) in Boston, where AcuityMD and Vericel will speak about AI in MedTech. About AcuityMD. AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies - including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD ranked No. 316 on the 2026 Inc. 5000 list of the fastest-growing private companies in America and was named to Forbes' 2025 "Next Billion-Dollar Startups" list - an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation. Media contact: Lisa Barbadora, Barbadora INK for AcuityMD +1 (610) 420-3413